![]() |
||||
|
|
||||
|
|
||||
ONCOLOGY: Trabectedin For The Treatment Of Relapsed Ovarian CancerFrom: Hope Waltman (anonymous@obgyn.net)Sat, 22 Nov 2008 06:50:07 -0600 (CST)
Ortho Biotech Announces NDA Submission For Trabectedin For The Treatment Of Relapsed Ovarian Cancer "Ortho Biotech Products, L.P. announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment option for these patients in the United States. http://www.medicalnewstoday.com/articles/130233.php " Regards, Hope Waltman, WHF Moderator http://www.hopeforfibroids.org
|
|
Return to ![]()
Report TECHNICAL Problems ONLY to: webmaster@obgyn.net
Last Updated: Wed Dec 2 06:56:19 2009
Women's Insurance Checklist from Auto Insurance Quote
home | medical professionals | women | industry | forums | international